Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570504 | 0.78 | LTA4H (0.42) | CYP2A13MAPK14PIK3CDPIK3CBPDE3B | |
| SCHEMBL24800721 | 0.77 | PIK3CA (0.33) | PDCD1CD274PIK3CDPIK3CB | |
| SCHEMBL22448155 | 0.76 | SLC5A2 (0.31) | — | |
| SCHEMBL22570601 | 0.73 | SLC5A1 (0.53) | — | |
| SCHEMBL22448152 | 0.73 | SLC5A1 (0.53) | — | |
| SCHEMBL25094461 | 0.73 | AAK1 (0.35) | PDCD1CD274MAPK14PIK3CDPIK3CB | |
| SCHEMBL5973653 | 0.70 | S1PR4 (0.36) | — | |
| SCHEMBL13183761 | 0.68 | PRMT6 (0.48) | CYP2A13 | |
| SCHEMBL12185865 | 0.68 | SLC5A2 (0.53) | — | |
| SCHEMBL4763681 | 0.67 | SNCA (0.33) | PDCD1CD274MAPK14PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3712147-B1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANGDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-10822365-B1 | SGLTS inhibitor and application thereof | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-10-22 | — | — | US | disclosed |
| EP-3712147-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | Shangdong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822365-B1 | SGLTS inhibitor and application thereof | SLC5A1, SLC5A2, SLC5A11 | CYP2A13 657/4885PDCD1 3048/4885CD274 3457/4885 |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SLC5A1, SLC5A2, SLC5A11 | CYP2A13 657/4885PDCD1 3048/4885CD274 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.